Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1992 1
1994 3
1995 4
1996 6
1997 6
1998 6
1999 3
2000 4
2001 7
2002 7
2003 10
2004 12
2005 9
2006 15
2007 5
2008 5
2009 4
2010 3
2011 1
2012 6
2013 3
2014 3
2015 3
2016 3
2017 1
2018 3
2019 3
2020 8
2021 4
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 16145740

150 results

Results by year

Filters applied: . Clear all
Page 1
Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C; 'Casodex' Early Prostate Cancer Trialists Group. Tyrrell CJ, et al. Radiother Oncol. 2005 Jul;76(1):4-10. doi: 10.1016/j.radonc.2005.06.005. Radiother Oncol. 2005. PMID: 16145740 Clinical Trial.
A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No. 6.
Iversen P, Tammela TL, Vaage S, Lukkarinen O, Lodding P, Bull-Njaa T, Viitanen J, Hoisaeter P, Lundmo P, Rasmussen F, Johansson JE, Persson BE, Carroll K; Scandinavian Prostatic Cancer Group (SPCG). Iversen P, et al. Eur Urol. 2002 Sep;42(3):204-11. doi: 10.1016/s0302-2838(02)00311-1. Eur Urol. 2002. PMID: 12234503 Clinical Trial.
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group. See WA, et al. J Urol. 2002 Aug;168(2):429-35. J Urol. 2002. PMID: 12131282 Clinical Trial.
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
Wirth M, Tyrrell C, Delaere K, Sánchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns C, Borchers T, Morris T, Armstrong J; 'Casodex' Early Prostate Cancer Trialists' Group. Wirth M, et al. Prostate Cancer Prostatic Dis. 2005;8(2):194-200. doi: 10.1038/sj.pcan.4500799. Prostate Cancer Prostatic Dis. 2005. PMID: 15931272 Clinical Trial.
150 results